Adlai Nortye Raises $150 Million in Oversubscribed Private Placement to Advance Cancer Pipeline
TipRanks (Thu, 16-Apr 10:16 AM ET)
Adlai Nortye jumps 19% on $150M private equity financing
Seeking Alpha News (Thu, 16-Apr 7:36 AM ET)
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Globe Newswire (Thu, 16-Apr 7:00 AM ET)
Globe Newswire (Thu, 12-Feb 4:00 AM ET)
Market Chameleon (Tue, 3-Feb 6:43 AM ET)
Market Chameleon (Tue, 3-Feb 2:37 AM ET)
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Globe Newswire (Tue, 3-Feb 7:00 AM ET)
Adlai Nortye Secures $230 Million Licensing Deal for Pan-RAS Inhibitor AN9025 in Greater China
Market Chameleon (Mon, 29-Dec 4:52 AM ET)
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Adlai Nortye Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ANL.
As of April 20, 2026, ANL stock price climbed to $16.60 with 808,171 million shares trading.
ANL has a beta of 2.88, meaning it tends to be more sensitive to market movements. ANL has a correlation of 0.06 to the broad based SPY ETF.
ANL has a market cap of $881.08 million. This is considered a Small Cap stock.
Last quarter Adlai Nortye Ltd. - American Depositary Shares reported $0 in Revenue and -$2.52 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$2.23.
The top ETF exchange traded funds that ANL belongs to (by Net Assets): CANC.
ANL has outperformed the market in the last year with a price return of +870.8% while the SPY ETF gained +36.0%. ANL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +822.2% and +102.9%, respectively, while the SPY returned +2.7% and +8.1%, respectively.
ANL support price is $14.08 and resistance is $17.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANL shares will trade within this expected range on the day.